Paradigm Asset Management Co. LLC Has $979,000 Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Paradigm Asset Management Co. LLC cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 43.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,600 shares of the biopharmaceutical company's stock after selling 8,100 shares during the period. Paradigm Asset Management Co. LLC's holdings in Gilead Sciences were worth $979,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Avior Wealth Management LLC boosted its position in Gilead Sciences by 1.2% during the 3rd quarter. Avior Wealth Management LLC now owns 9,422 shares of the biopharmaceutical company's stock worth $782,000 after purchasing an additional 108 shares during the period. Southland Equity Partners LLC boosted its position in Gilead Sciences by 3.6% in the 4th quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company's stock valued at $289,000 after buying an additional 110 shares during the last quarter. Concord Asset Management LLC VA boosted its position in Gilead Sciences by 3.8% in the 3rd quarter. Concord Asset Management LLC VA now owns 3,056 shares of the biopharmaceutical company's stock valued at $256,000 after buying an additional 111 shares during the last quarter. Berkshire Bank boosted its position in Gilead Sciences by 3.4% in the 4th quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company's stock valued at $314,000 after buying an additional 111 shares during the last quarter. Finally, TFB Advisors LLC boosted its position in Gilead Sciences by 1.2% in the 3rd quarter. TFB Advisors LLC now owns 9,397 shares of the biopharmaceutical company's stock valued at $788,000 after buying an additional 116 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

NASDAQ:GILD traded down $0.08 during trading hours on Friday, reaching $109.95. 9,729,048 shares of the company's stock were exchanged, compared to its average volume of 7,379,648. The company has a market capitalization of $137.03 billion, a P/E ratio of 297.16, a price-to-earnings-growth ratio of 0.71 and a beta of 0.18. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $111.03. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The business's 50-day simple moving average is $95.41 and its two-hundred day simple moving average is $88.73.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be given a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.87%. The ex-dividend date is Friday, March 14th. This is an increase from Gilead Sciences's previous quarterly dividend of $0.77. Gilead Sciences's dividend payout ratio is 832.43%.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 248,645 shares of the company's stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the sale, the chief financial officer now owns 138,919 shares in the company, valued at approximately $12,886,126.44. This represents a 64.16 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the sale, the director now directly owns 8,920 shares of the company's stock, valued at $815,198.80. This trade represents a 43.21 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 713,000 shares of company stock worth $67,945,181. 0.16% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on GILD shares. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, February 12th. Citigroup assumed coverage on shares of Gilead Sciences in a research note on Thursday, November 14th. They set a "buy" rating and a $125.00 price objective on the stock. Truist Financial increased their price objective on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a "hold" rating in a research note on Friday, November 8th. Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and increased their price objective for the stock from $80.00 to $120.00 in a research note on Tuesday, February 18th. Finally, Royal Bank of Canada upped their target price on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a research report on Wednesday, February 12th. Eleven analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have issued a strong buy rating to the company's stock. According to MarketBeat.com, Gilead Sciences currently has a consensus rating of "Moderate Buy" and an average target price of $102.08.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.